this morning good our joining call thank and everyone morning. Thanks, you Kathy for and
safe. that acknowledge started, listening to you I do healthy I of your families and hope situation are want the Before and get today, COVID-XX all
with member and network specialist to of a more has pharma as longstanding papers, XXX several Pravin meetings been authored who invited internationally major has worldwide. by visiting on investigator and a in His has Day of Chairman editorial and Honor him XXX at introducing Academy society educational principal a in universities Retina And of of board as in member professor trials. Let chapters, retinal has Pravin of journals. book from recognized relationships serve Ophthalmology’s researcher begin lecture is Senior over Europe, medical American research the largest the He’s directors been largest of Dr. clinical board multi-center United of team, Annual previously management Award and Retina and served been marquee previously elected our prestigious he as medical today Ophthalmology. Specialists, served the major He is the States, Meeting. American a the for globally and has to the recognized the XX clinical Board has earns several of the the at also and newest American and executive society EURETINA. Society Pravin ophthalmic Pravin contribution than the extensive biotech elected me as Dugel. Academy retinal community. the Subspecialty been retinal the
to XX also contributions over Pravin retinal to his has and the In to biotech pharma addition community, consulted accomplishments and companies. many
as Executive build potential help helping believe stakeholders. with developing diseases. investors as As opportunities expand retinal Pravin R&D instrumental the company’s our for lead Vice strategy Strategy our build we transformative and therapeutics collaborators, advance in Chief therapy therapies will and leadership treating us our alliances and as of in future our Business we programs and be that targeting will experience portfolio Officer, President retinal other well portfolio Pravin’s and multiple new diseases, gene could
will the from In few We hear moments to join company. Pravin are a have Pravin. excited you
believe and results, dollar potential or positions pivotal a moment IVERIC bio from a trial in for us our late-stage which to AMD. registration We company watershed atrophy, with clinical secondary a we market. data geographic Zimura as entered for purposes, of were the as trial macular or OPHXXXX GA, positive OPHXXXX XXXX These qualify in screening age-related degeneration, multibillion
pivotal we Zimura and X a changed Although have Zimura to designation now qualified have Recall pivotal the Phase our from hit significance phase results or X trial. and a trial as trial has observed Phase had refer changed, threshold not in not results X milligram OPHXXXX would OPHXXXX both the milligram treatment groups. that this not that view the of will we as X/X statistical
in our and favorable safety the March to safety clinical physicians as enrollment trial, the staff trial outset as a positive on X the their process has of XXXX. patient caregivers, and which main This Phase track efficacy began patients of Following was our observed in the we initiating and clinical we priority this this always health and their trial, call well second collaborators. profile terrible and and employees Zimura pandemic, From of initiate results been of ISEEXXXX.
clinical that engaged that expeditiously to so a these XXXX. and the details an unwavering with trial in support and for position the the our so. operations of activities, dedication to potential to we staffs, trial of Due his to be we in clinical and review, some of will to we as chose Kourous, keep as patient identification sites. for some including patients, have Therefore will trial, the March, due our pause into our enrollment patients strategy initiatives and initiative appropriate go Zimura with activate put of begin we their sites place aggressive we well other taken continued initiation clinical investigators additional and in in team, time experienced enrolling of ISEEXXXX progress as investigators do to along determine as of the soon the
unprecedented brought The XXXX times. of has beginning
enrolling it us begin the activities at January, and clinical the months we bio. had has clinical design patients also completed a of announcements, our ISEEXXXX of time However, clinical here within to for necessary of productive number IVERIC trial, a X In been team the announced operations at sites.
begin enrollment. to poised the initiate believe as I to COVID-XX a we we level enrollment safe As our mentioned, investigators that as improves are to situation previously soon and is patient
by initial gather Phase at of the line are point safety to we track data. of is from reported XXXX. we data our Following data Again, second primary that clinical end receive quarter October the X to the XX-month end OPHXXXX top the the additional the XXXX, of time data purpose the XX-month on trial positive
for Fast a drug look Track with rolling important Designation with FDA. frequent We application. of AMD. and criteria U.S. the including the working offers the review If were of GA Track and benefits, to are forward Fast the to we Designation relevant close for for eligibility the potential granted from priority secondary treatment the met, new FDA submission FDA Zimura interactions
Our disease, be to of Stargardt ongoing recessive track on Phase orphan Xb an autosomal the of data clinical Zimura retinal second year. for this trial the treatment inherited continues top line disease of available for half during
pandemic, including impact the closely However, COVID-XX the investigators. our of we continue patients on and this monitor trial, to
our to we Zimura priority, portfolio our inherited retinal our on top bringing orphan Although gene patients focus to therapy diseases. is in continue
and collaborators the of at During in manufacturers. close as this School, Medical contact COVID-XX Massachusetts Pennsylvania remain we the as of our Florida, University University with of our pandemic, University well
active shutdowns retinal temporary XXXX our begin expected intended IC-XXX, trial plan treat patients first been the an for we with due file COVID-XX, plan at academic by maintain studies intended temporary have centers there are an history to to is all to IC-XXX, collaborators. treat dialogue activities Natural and IND-enabling While adRP, rhodopsin-mediated which ongoing, of initiate clinical the Phase which diseases, XXXX. half clinical and enrolling and Phase during and the end XXXX. is slowdowns of and we half BESTX-related of XXXX first we on to or a X/X to trial of a early the in continues track, X/X during IND
net the identify the minigene are forward half a to we XXXX. our Our for XXXX. million stock sheet ongoing, approximately warrants, and capital cash of to for our successful December have lead look equivalents program and believe We to sufficient of into our COVID-XX of we they providing as common balance planned programs are actions to of expenditures of construct of cash during proceeds of you expect updates strengthen as in treatment completion XXXX. of all that taken minigene also pre-funded our the prior offering the these to includes $XX.X pandemic We LCAXX public the The progress. that miniCEPXXX the resulting operations currently second follow-on beginning of our programs in and and the fund company to
selectively, continue development explore to business our continue for Zimura, commercialization options continue In potential addition, including and of development opportunities. efforts we future we to potential as collaboration aggressively, and out-license but
effectively managing of this we pandemic, our the business shareholders. remain predict While caused our for and cash duration on depth value by focus crisis by disruption global to committed on of this impact position of we creating the the mitigating cannot
Pravin. I’d the that, call to like now over turn With to
